(:DOVA)

Oct 29, 2019 02:54 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Reminds DOVA, TRCB, EEI, and UCFC Shareholders About Its Ongoing Investigations
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP 1500 Broadway, 16th...
Oct 28, 2019 10:28 am ET
Bragar Eagel & Squire, P.C. Announces that it Is Investigating the Boards of Directors of Avedro, Dova, SemGroup, and United Community on behalf of Stockholders and Encourages Investors to Contact the
Bragar Eagel & Squire, P.C. announces to investors that it is investigating potential claims on behalf of stockholders of Avedro, Inc. (NASDAQ: AVDR), Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), SemGroup Corporation (NYSE: SEMG), and United...
Oct 23, 2019 04:27 pm ET
MERGER ALERT – RARX, DOVA, and SEMG: Levi & Korsinsky, LLP Notifies Investors of Investigations Concerning the Sale of these Companies
The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies. Ra Pharmaceuticals, Inc. (NASDAQ: RARX)...
Oct 22, 2019 03:11 pm ET
Merger Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders – DOVA, VSI, PRTO
Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Dova Pharmaceuticals, Inc. (NASDAQ: DOVA)The investigation concerns whether Dova and its board of directors violated the federal securities laws...
Oct 18, 2019 05:02 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Reminds OLBK, DOVA, TRCB, and EEI Shareholders About Its Ongoing Investigations
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP 1500 Broadway, 16th...
Oct 17, 2019 11:23 am ET
Moore Kuehn, PLLC Encourages Milacron Holdings Corp. (MCRN), Ecology & Environmental, Inc. (EEI), Pivotal Software, Inc. (PVTL), and Dova Pharmaceuticals, Inc. (DOVA) Investors to Contact Firm
NEW YORK, Oct. 17, 2019 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City, is investigating potential claims involving the directors and officers regarding possible breaches of fiduciary duties and other violations of law related to the following companies' entry into merger agreements:
Oct 16, 2019 01:12 pm ET
MERGER ALERT – RARX, DOVA, and ROAN: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies
The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies. Ra Pharmaceuticals, Inc. (NASDAQ: RARX)...
Oct 12, 2019 07:32 pm ET
Dova Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Dova Pharmaceuticals, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – DOVA
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) to Swedish Orphan Biovitrum AB (“Sobi”) is fair to Dova shareholders. On behalf of Dova shareholders, Halper Sadeh...
Oct 11, 2019 04:19 pm ET
STOCKHOLDER ALERT: Monteverde & Associates PC is Investigating the Following Merger
NEW YORK, Oct. 11, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating:
Oct 08, 2019 04:11 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Reminds HLND, TNCB, PGNX, DOVA Shareholders About Its Ongoing Investigations
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP 1500 Broadway, 16th...
Oct 07, 2019 05:13 pm ET
MERGER ALERT –TSG, DOVA, ROAN, and HLND: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies
The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies. The Stars Group Inc. (NASDAQ: TSG) Merger...
Oct 04, 2019 06:12 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Investigates Dova Pharmaceuticals, Inc.
NEW YORK, Oct. 4, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Dova Pharmaceuticals, Inc. ("Dova" or the "Company") (NASDAQ: DOVA) in connection with the proposed acquisition of the Company by Swedish Orphan Biovitrum AB ("Sobi") (OM: SOBI).  Under the terms of the acquisition agreement, DOVA shareholders will receive $27.50 in cash and a contingent value right entitling each DOVA shareholder to an additional $1.50 upon regulatory approval of DOPTELET, the Company's treatment for chemotherapy-induced thromb
Oct 02, 2019 11:03 am ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Dova Pharmaceuticals, Inc. to Swedish Orphan Biovitrum AB is Fair to Shareholders
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Dova Pharmaceuticals, Inc. (“Dova” or the “Company”) (NASDAQ: DOVA) stock prior to September 30, 2019. You are hereby notified that Levi &...
Sep 30, 2019 06:33 pm ET
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) on Behalf of Dova Shareholders and Encourages Dova Investors to Contact the Firm
NEW YORK, Sept. 30, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) on behalf of Dova shareholders concerning the proposed merger with Swedish Orphan Biovitrum AB.
Sep 30, 2019 09:57 am ET
Shareholder Alert: Ademi & O'Reilly, LLP Investigates whether Dova Pharmaceuticals, Inc. has obtained a Fair Price in its sale to Swedish Orphan Biovitrum AB
MILWAUKEE, Sept. 30, 2019 /PRNewswire/ -- Ademi & O'Reilly, LLP is investigating Dova Pharmaceuticals, Inc. (Nasdaq: DOVA) for possible breaches of fiduciary duty and other violations of the law in connection with the sale of Dova to Swedish Orphan Biovitrum.
Sep 30, 2019 09:31 am ET
Thinking about buying stock in Aurora Cannabis, Dova Pharmaceuticals, JD.Com, Nike, or Wells Fargo?
NEW YORK, Sept. 30, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, DOVA, JD, NKE, and WFC.
Sep 30, 2019 02:00 am ET
Dova Pharmaceuticals to be Acquired by Swedish Orphan Biovitrum AB (Sobi)
Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) announced today it has entered into an agreement and plan of merger with Swedish Orphan Biovitrum AB (Sobi) (OM:SOBI). Under the terms of the agreement, an indirect subsidiary of Sobi will commence a tender...
Sep 25, 2019 04:15 pm ET
Dova Pharmaceuticals to Present at 2019 Cantor Global Healthcare Conference
Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Jason Hoitt, Chief Commercial Officer, will present a company overview at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2, 2019 at 4:10 p.m. ET in New York, NY. A...
Sep 03, 2019 04:30 pm ET
Dova Pharmaceuticals to Present at Upcoming Investor Conferences
Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Dr. David Zaccardelli, President & Chief Executive Officer, will present company overviews at two upcoming investor conferences: H.C. Wainwright 21st Annual Global Investment...
Aug 06, 2019 04:15 pm ET
Dova Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare Conference
Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Jason Hoitt, Chief Commercial Officer, will present a company overview at the 2019 Wedbush PacGrow Healthcare Conference on Tuesday, August 13, 2019 at 2:30 p.m. ET in New York, NY. A...
Aug 06, 2019 07:00 am ET
Dova Pharmaceuticals Reports Second Quarter 2019 Operating and Financial Results
Dova Pharmaceuticals, Inc. (Nasdaq: DOVA), a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is a high unmet need, today reported its operating and financial results for the...
Jul 30, 2019 04:15 pm ET
Dova Pharmaceuticals to Announce Second Quarter 2019 Financial Results on August 6, 2019
Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) will host a conference call on Tuesday, August 6, 2019 at 9:00 a.m. ET to discuss second quarter 2019 financial results and recent operational highlights. A question-and-answer session will follow Dova's...
Jul 19, 2019 07:30 am ET
Dova Pharmaceuticals Announces DOPTELET® (avatrombopag) Now Commercially Available in the United States for Treatment of Chronic Immune Thrombocytopenia (ITP)
Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases where there is a high unmet need, today announced the commercial availability of DOPTELET...
Jun 27, 2019 08:05 am ET
Dova Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for DOPTELET® (avatrombopag) for Treatment of Chronic Immune Thrombocytopenia (ITP)
Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases where there is a high unmet need, today announced the U.S. Food and Drug Administration (FDA)...
Jun 25, 2019 08:00 am ET
Dova Pharmaceuticals Announces European Union Marketing Authorization for DOPTELET® (avatrombopag) for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease
Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases where there is a high unmet need, today announced that the European Commission (EC) has granted...
Jun 24, 2019 08:00 am ET
Dova Pharmaceuticals Announces Four Presentations on Avatrombopag in Patients with Chronic Immune Thrombocytopenia at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress
Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced the Company will present four abstracts with data from studies of avatrombopag in patients with chronic immune thrombocytopenia (ITP) at the 65th International Society on Thrombosis and...
May 28, 2019 04:30 pm ET
Dova Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference
Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Dr. David Zaccardelli, President and Chief Executive Officer, will present a company overview at the Jefferies 2019 Global Healthcare Conference on Tuesday, June 4, 2019 at 11:00 a.m....
May 23, 2019 09:06 am ET
Wedbush Securities Senior Vice President of Equity Research Laura Chico, Ph.D. Initiates Coverage on Six Stocks in the Healthcare and BioTech Space - ACER, ACOR, ALNX, BIIB, DOVA and SAGE
LOS ANGELES, May 23, 2019 /PRNewswire/ -- Wedbush Securities is pleased to announce that Senior Vice President of Equity Research, Laura Chico, Ph.D., initiates coverage on six stocks in the Healthcare and BioTech space. Initiations are on the following: Acer Therapeutics Inc. (ACER), Acorda Therapeutics, Inc. (ACOR), Alexion Pharmaceuticals (ALXN), Biogen Inc (BIIB), Dova Pharmaceuticals, Inc. (DOVA), and Sage Therapeutics, Inc. (SAGE).  
May 20, 2019 07:00 am ET
Dova Pharmaceuticals to Present at the UBS Global Healthcare Conference
Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Jason Hoitt, Chief Commercial Officer, will present a company overview at the UBS Global Healthcare Conference on Monday, May 20, 2019 at 2:00 p.m. ET in New York, NY.  A live audio...
May 07, 2019 07:00 am ET
Dova Pharmaceuticals Reports First Quarter 2019 Operating and Financial Results
Dova Pharmaceuticals, Inc. (Nasdaq: DOVA), a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is a high unmet need, today reported its operating and financial results for the...
Apr 29, 2019 07:30 am ET
Dova Pharmaceuticals Receives Positive Opinion from CHMP for DOPTELET® (avatrombopag) for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease
Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European  Medicines Agency (EMA) adopted a positive opinion for the use of DOPTELET® for the treatment of severe...
Apr 10, 2019 07:45 am ET
Investor Expectations to Drive Momentum within Analog Devices, Atara Biotherapeutics, Cigna, Solaris Oilfield Infrastructure, Erie Indemnity, and Dova Pharmaceuticals — Discovering Underlying Factors
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Analog Devices, Inc. (NASDAQ:ADI), Atara Biotherapeutics, Inc....
Apr 02, 2019 04:05 pm ET
Dova Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference
Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Jason Hoitt, Chief Commercial Officer, will present a company overview at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 9, 2019 at 9:30 a.m. BST (4:30 a.m. EDT)...
Mar 05, 2019 04:45 pm ET
Dova Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference
Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Dr. David Zaccardelli, President and Chief Executive Officer, will present a company overview at the Cowen and Company 39th Annual Health Care Conference on Wednesday, March 13, 2019 at...
Mar 05, 2019 07:00 am ET
Dova Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Operating and Financial Results
Dova Pharmaceuticals, Inc. (Nasdaq: DOVA), a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is a high unmet need, today reported its operating and financial results for the...
Feb 26, 2019 08:00 am ET
Investor Expectations to Drive Momentum within Newmont Mining, Albemarle, Abraxas Petroleum, Osisko Gold Royalties, Toro, and Dova Pharmaceuticals — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Newmont Mining Corporation (NYSE:NEM), Albemarle Corporation...
Feb 19, 2019 04:15 pm ET
Dova Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on March 5, 2019
Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) will host a conference call on Tuesday, March 5, 2019 at 9:00 a.m. ET to discuss fourth quarter and full year 2018 financial results and recent operational highlights. A question-and-answer session will...
Feb 19, 2019 08:00 am ET
Dova Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference
Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Dr. David Zaccardelli, President and Chief Executive Officer, will present a company overview at the 8th Annual SVB Leerink Global Healthcare Conference on Friday, March 1, 2019 at...
Jan 02, 2019 04:15 pm ET
Dova Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Dr. David Zaccardelli, President and Chief Executive Officer, will present a company overview at the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019 at 3:00...
Dec 20, 2018 04:15 pm ET
Dova Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dova Pharmaceuticals, Inc. (Nasdaq: DOVA), a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is a high unmet need, today announced that on December 19, 2018, the Compensation...
Dec 17, 2018 07:30 am ET
Dova Pharmaceuticals Announces Management Changes
Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is a high unmet need, today announces that David Zaccardelli, Pharm. D., has been...
Nov 27, 2018 08:25 am ET
Report: Exploring Fundamental Drivers Behind ForeScout Technologies, GNC, Dova Pharmaceuticals, CymaBay Therapeutics, Adesto Technologies, and Clearside Biomedical — New Horizons, Emerging Trends, and
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of ForeScout Technologies, Inc. (NASDAQ:FSCT), GNC Holdings, Inc....
Nov 08, 2018 04:05 pm ET
Dova Pharmaceuticals Reports Third Quarter 2018 Operating and Financial Results
Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is a high unmet need, today reported its operating and financial results for the...
Nov 06, 2018 04:05 pm ET
Dova Pharmaceuticals to Present at Upcoming Investor Conferences
Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that the management team will present a company overview at four upcoming investor conferences: On Tuesday, November 13, 2018, Dova will present at the Stifel 2018 Healthcare Conference at...
Nov 05, 2018 07:00 am ET
Dova Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for DOPTELET® (avatrombopag) for the Treatment of Chronic Immune Thrombocytopenia (ITP)
Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is a high unmet need, today announced the U.S. Food and Drug Administration (FDA) has...
Nov 01, 2018 04:05 pm ET
Dova Pharmaceuticals to Announce Third Quarter 2018 Financial Results on November 8, 2018
Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) will host a conference call on Thursday, November 8, 2018 at 4:30 p.m. ET to discuss third quarter 2018 financial results and recent operational highlights. A question-and-answer session will follow Dova's...
Oct 16, 2018 08:10 am ET
Analysis: Positioning to Benefit within Kopin, MDC Partners, Dova Pharmaceuticals, Revlon, Imprimis Pharmaceuticals, and Minerva Neurosciences — Research Highlights Growth, Revenue, and Consolidated R
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Kopin Corporation (NASDAQ:KOPN), MDC Partners Inc. (NASDAQ:MDCA), Dova...
Sep 27, 2018 07:45 am ET
Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET® (Avatrombopag)
Dova Pharmaceuticals, Inc. (“Dova”) (NASDAQ: DOVA), a specialty pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is a high unmet need, and Salix Pharmaceuticals (“Salix”), one of...
Sep 26, 2018 04:15 pm ET
Dova Pharmaceuticals to Present at Upcoming Investor Conferences
Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at two upcoming investor conferences in New York: Tuesday, October 2, 2018, Dova will present at...
Sep 11, 2018 04:45 pm ET
Dova Pharmaceuticals to Host Investor & Analyst Day on September 20, 2018
Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a specialty pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is a high unmet need, today announced that the Company will host a live...
Sep 04, 2018 04:05 pm ET
Dova Pharmaceuticals Submits Supplemental New Drug Application for DOPTELET® (avatrombopag) for the Treatment of Chronic ITP
Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a specialty pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is a high unmet need, today announced the submission of a supplemental New...
Aug 16, 2018 07:35 am ET
Analysis: Positioning to Benefit within Amtech, NL Industries, Dova Pharmaceuticals, Sientra, Dorian LPG, and Assembly Biosciences — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amtech Systems, Inc. (NASDAQ:ASYS), NL Industries, Inc. (NYSE:NL), Dova...
Aug 09, 2018 04:01 pm ET
Dova Pharmaceuticals Reports Second Quarter 2018 Operating and Financial Results
Dova Pharmaceuticals, Inc. (NASDAQ:DOVA), a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, today reported its operating and financial results for the...
Jul 26, 2018 04:05 pm ET
Dova Pharmaceuticals to Announce Second Quarter 2018 Financial Results on August 9, 2018
Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) will host a conference call on Thursday, August 9, 2018 at 4:30 p.m. ET to discuss second quarter 2018 financial results and recent operational highlights. A question-and-answer session will follow Dova's...
Jun 25, 2018 07:00 am ET
Nancy J. Wysenski Joins Dova Pharmaceuticals’ Board of Directors
Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that Nancy J. Wysenski will join Dova’s Board of Directors effective immediately. In addition to her board responsibilities, Ms. Wysenki will also serve on both the Compensation Committee and...
Jun 04, 2018 07:00 am ET
Dova Pharmaceuticals Announces Publication of Pivotal Phase 3 Data and Upcoming Congress Presentations for DOPTELET® (avatrombopag)
Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced the recent online publication of its pivotal Phase 3 trial data on the use of DOPTELET®  (avatrombopag) for the treatment of thrombocytopenia in patients with chronic liver disease (CLD) in...
May 31, 2018 07:00 am ET
Dova Pharmaceuticals Announces Availability of DOPTELET® in the United States
Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced the availability of DOPTELET in the United States for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure. DOPTELET...
May 29, 2018 05:00 pm ET
Dova Pharmaceuticals to Present at Jefferies 2018 Healthcare Conference
Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at the Jefferies 2018 Global Healthcare Conference on Tuesday, June 5, 2018 at 1:30 p.m. ET in New...
May 25, 2018 08:15 am ET
Market Trends Toward New Normal in inTest, Westamerica, Simmons First National, Dova Pharmaceuticals, ScanSource, and Horizon Bancorp (IN) — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of inTest Corporation (NYSE:INTT), Westamerica Bancorporation (NASDAQ:WABC),...
May 21, 2018 12:43 pm ET
Dova Pharmaceuticals Announces U.S. FDA Approval of DOPTELET® (avatrombopag)
Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced the U.S. Food and Drug Administration (FDA) has completed their Priority Review and approved DOPTELET® (avatrombopag) for the treatment of thrombocytopenia in adult patients with chronic...
May 21, 2018 11:00 am ET
Should you buy stock in ADOMANI, Baidu, Dova Pharmaceuticals, LaSalle Hotel Properties or Snap Inc?
NEW YORK, May 21, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADOM, BIDU, DOVA, LHO, and SNAP.
May 09, 2018 04:05 pm ET
Dova Pharmaceuticals Reports First Quarter 2018 Operating and Financial Results
Dova Pharmaceuticals, Inc. (NASDAQ:DOVA), a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, today reported its operating and financial results for the...
May 02, 2018 04:30 pm ET
Dova Pharmaceuticals to Announce First Quarter 2018 Financial Results on May 9, 2018
Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) will host a conference call on Wednesday, May 9, 2018 at 4:30 p.m. ET to discuss first quarter 2018 financial results and recent operational highlights. A question-and-answer session will follow Dova's...
Apr 03, 2018 07:55 am ET
Investor Expectations to Drive Momentum within Horizon Bancorp (IN), Allegiant Travel, Littelfuse, Dova Pharmaceuticals, BOK Financial, and Northfield — Discovering Underlying Factors of Influence
NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Horizon Bancorp (IN) (NASDAQ:HBNC), Allegiant Travel...
Mar 19, 2018 08:00 am ET
Dova Pharmaceuticals Signs Exclusive Distribution Agreement with Fosun Pharma For Mainland China and Hong Kong
DURHAM, N.C., March 19, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA), a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, entered into an agreement through...
Mar 08, 2018 08:00 am ET
Dova Pharmaceuticals to Present at Cowen 38th Annual Health Care Conference
DURHAM, N.C., March 08, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at the Cowen 38th Annual Health Care Conference on Wednesday, March...
Feb 22, 2018 07:30 pm ET
Dova Pharmaceuticals, Inc. Announces Pricing of Offering of Common Stock
DURHAM, N.C., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet need, today announced the pricing of an...
Feb 20, 2018 04:05 pm ET
Dova Pharmaceuticals, Inc. Announces Proposed Offering of Common Stock
DURHAM, N.C., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet need, today announced that it has commenced...
Feb 15, 2018 04:05 pm ET
Feb 12, 2018 05:00 pm ET
Dova Pharmaceuticals to Present at Leerink Partners 7th Annual Global Healthcare Conference
DURHAM, N.C., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at the Leerink Partners 7th Annual Global Healthcare Conference on Wednesday,...
Feb 12, 2018 04:15 pm ET
Dova Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results on February 15, 2018
DURHAM, N.C., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) will host a conference call on Thursday, February 15, 2018 at 4:30 p.m. EST to discuss fourth quarter and full year 2017 financial results and recent...
Feb 02, 2018 07:30 am ET
New Research: Key Drivers of Growth for Dova Pharmaceuticals, Park Electrochemical, Corium International, Sirius XM, Home Depot, and Walgreens Boots Alliance — Factors of Influence, Major Initiatives
NEW YORK, Feb. 02, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dova Pharmaceuticals, Inc. (NASDAQ:DOVA), Park Electrochemical...
Jan 30, 2018 07:00 am ET
Dova Pharmaceuticals Announces the Appointment of Mark W. Hahn as Chief Financial Officer
DURHAM, N.C., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced the appointment of Mark W. Hahn as the company’s Chief Financial Officer.  A veteran Chief Financial Officer of the biotech industry, Mr. Hahn previously...
Jan 03, 2018 04:30 pm ET
Dova Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
DURHAM, N.C., Jan. 03, 2018 (GLOBE NEWSWIRE) --  Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at the J.P. Morgan 36th Annual Healthcare Conference on Monday, January...
Dec 04, 2017 04:30 pm ET
Dova Pharmaceuticals Announces Four Presentations at the 59th American Society of Hematology Annual Meeting
DURHAM, N.C., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that the Company will present four abstracts, three of which will be oral presentations, with data from Phase 3 clinical trials of avatrombopag in...
Nov 21, 2017 08:30 am ET
Dova Pharmaceuticals to Present at Evercore ISI Conference
DURHAM, N.C., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at the Evercore ISI Biopharma Catalyst/Deep Dive Conference on Thursday, November...
Nov 10, 2017 08:30 am ET
Dova Pharmaceuticals to Present at Jefferies 2017 London Healthcare Conference
DURHAM, N.C., Nov. 10, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at the Jefferies 2017 London Healthcare Conference on Wednesday, November 15,...
Nov 09, 2017 04:05 pm ET
Nov 02, 2017 04:30 pm ET
Dova Pharmaceuticals to Announce Third Quarter 2017 Financial Results on November 9, 2017
DURHAM, N.C., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet need, will host a conference call...
Nov 02, 2017 04:30 pm ET
Dova Pharmaceuticals to Announce Third Quarter 2017 Financial Results on November 9, 2017
DURHAM, N.C., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet need, will host a conference call on Thursday, November 9, 2017 at 4:30 p.m. EST to discuss third quarter 2017 financial results and recent operational highlights. A question-and-answer session will follow Dova's remarks....
Oct 10, 2017 04:30 pm ET
Dova Pharmaceuticals to Present Phase 3 Avatrombopag Data at the 2017 Liver Meeting of the American Association for the Study of Liver Diseases (AASLD)
Detailed Safety and Efficacy Results from ADAPT-1 and ADAPT-2 Phase 3 Trials to be Reported in Oral Presentation...
Sep 20, 2017 04:15 pm ET
Dova Pharmaceuticals to Present at 2017 Leerink Partners Rare Disease Roundtable
DURHAM, N.C., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at the 2017 Leerink Partners Rare Disease Roundtable Series on Wednesday, September 27, 2017 at 9:30 a.m. EDT in New York City....
Aug 10, 2017 04:05 pm ET
Dova Pharmaceuticals Reports Second Quarter 2017 Operating and Financial Results
NDA submission for avatrombopag expected in the third quarter of 2017...
Aug 03, 2017 04:30 pm ET
Dova Pharmaceuticals to Announce Second Quarter 2017 Financial Results on August 10, 2017
DURHAM, N.C., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet need, will host a conference call on Thursday, August 10, 2017 at 4:30 p.m. EDT to discuss second quarter 2017 financial results and recent operational highlights. A question-and-answer session will follow Dova's remarks....
Jun 28, 2017 10:36 pm ET
Dova Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
DURHAM, N.C., June 28, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet need, today announced the pricing of its initial public offering of 4,415,000 shares of its common stock at a public offering price of $17.00 per share, for total gross proceeds of approximately $75.1 million.  In addition, Dova has granted the underwriters a 30-day option to purchase up to an additional 662,250 shares of common stock at the public offering price, l...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.